Liva Healthcare, a digital healthcare platform offering “human-led therapeutic intervention programmes” for lifestyle-related chronic diseases such as type 2 diabetes, has announced its acquisition of Momenta, a provider of healthy lifestyle solutions, as part of its international growth strategy.
The purchase, made for an undisclosed sum, is hoped to “significantly” increase Liva’s reach and help it to emerge as a “major international provider of evidence-based therapeutic lifestyle interventions”, supported by Momenta’s existing provision and licensing of digital, virtual, and in-person healthy lifestyle programmes to NHS organisations and local authorities in the UK.
This latest acquisition comes amidst reports that Liva has successfully secured additional funding for its growth plans, with investors including MIG, Santos, and MajInvest.
Momenta’s CEO, Harry MacMillan, spoke of his “delight” to be joining forces with Liva, adding: “Our combined track records in programme and platform development and digital, virtual and in-person delivery are highly complementary. Liva’s digital platform will enable many more people across the UK and beyond to benefit from Momenta’s expert-developed chronic disease management programmes.”
Health tech funding and acquisitions
Last month, Patients Know Best announced it had secured a £6 million loan to help scale its digital personal health record platform and expand internationally. The funding is being supported by alternative finance provider, Growth Lending, to support Patients Know Best’s growth strategy.
UK health tech startup, Kidney Beam, received £610,000 in seed funding to help with improving virtual kidney care. The Kidney Beam app offers a range of physio-led virtual exercises, education, nutrition and wellbeing programmes specifically designed for people with kidney disease. With the funding, Kidney Beam plans to expand its reach into more unrepresented communities to “enhance the usability of its platform and forge new partnerships”. The funding comes after a clinical trial by Kidney Research UK and Kings College Hospital London, which reported a “significant improvement” in quality-of-life among those using Kidney Beam’s 12-week digital rehabilitation programme.
Earlier in February, London and Derby-based digital messaging platform Alertive secured £3.7 million from private investors to drive its UK expansion, announcing plans to “continue breaking down communication barriers within healthcare teams by integrating more third-party systems and enhancing workflows”. The platform has been developed to meet requirements for task management and communication within healthcare environments, and is currently being used in 25 hospitals across 15 NHS trusts, with a reported 50,000 users.
